Different cell populations of renal cell carcinoma : relevance for tumor stem cells
Prostate stem cells are CD133/ABCG2/EpCAM-positive, aldefluor-low, and can regenerate prostate epithelial cell cultures : 002
Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the prostate : 003
Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis : 004
Accumulation of progenitor cells in the luminal epithelial cell layer in a targeted Pten knockout mouse prostate cancer model : 005
Target antigen and regulatory T cell in experimental autoimmune prostatitis (EAP) : 006
Bladder cancer prognosis in relationship to variation in 108 genes coding for proteins involved in inflammatory pathways : 007
Tumor-associated trypsin inhibitor (TATI, SPINK1), but not trypsinogen-1, is associated with outcome after radical prostatectomy as evaluated by oligonucleotide and tissue microarrays in prostate cancer : 008
Discovering an organ-specific cell permeable peptide as an imaging probe for detecting metastasized bladder cancer : 009
TMPRSS2-ERG rearrangement in prostate cancer : 010
Clusterin is a very short half-life, poly-ubiquitinated protein controlling cell growth and proliferation in prostate cancer metastatic cells : 011
Epigenetic induction of Igf2 and H19 with choline and methionine deficiency in the mouse prostate : 012
A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model : OP01
Pegylated trispecific disulfide linked Fv (sdFv) targeting epitopes of EGFR, RANKL, and PTHrP conjugated covalently with SATA to bcl-2 phosphorylating agent vinorelbine- tartrate eradicated osteo-blastic, and osteolytic skeletal metastases of hormone refractory prostate cancer (mHRPC) by inducing ADCC, AMP, type I,II,III PCD, and inhibiting proliferation of tumor associated, and bone microvascular endothelial cells : OP02
Isolation of prostate stem/progenitor cells using a sphere forming assay : OP03
The dysregulation of three-dimensional specific genes play a significant role in prostate cancer development : OP04
Twist, a novel androgen-regulated gene is a target for Nkx3.1 in prostate cancer cells : OP05
Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence : OP06
SOCS-3 is upregulated by androgens in prostate cancer cells and exerts inhibitory effects on ar-mediated proliferation : OP07
Identifying molecular factors in androgen receptor nucleocytoplasmic trafficking : OP08
Human prostate endothelial cells as a first-line target for androgens : OP09
Prostate cancer cell proliferation involves cell cycle phase-dependent interaction of androgen receptor with the enzymes of DNA synthesis : OP10
Prohibitin and coflilin are smad-indepen-dent mediators of TGF-β signaling in prostate cancer cells : OP011
Testosterone stimulated growth of the rat prostate may be driven by tissue hypoxia and HIF-1α : OP012
VHL gene mutations in renal cancer are not predictive of hypoxic gene regulation or dissemination of cancer cells : OP013
Hypoxia regulates tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induced apoptosis in normal prostate epithelial cells : OP014
Prostate cancer cells secrete IL-4 an induce an M2 phenotype in infiltrating macrophages : OP015
Characterization of prostate specific inflammation in an inducible mouse model : OP016
Dendritic cell prostate cancer vaccine is enhanced by inhibiting the SH2-domain-containing phosphatase, SHP-1 : OP017
Sutent® treatment leads to decreased uptake of mAb cG250 in RCC : OP018
Molecular identification of microorganisms associated with prostate cancer : OP019
Hedgehog signaling and proliferative inflammatory atrophy : OP020
RNASEL and its role in Irish prostate cancer patients : OP021
Decreased Nrf2 expression and increased reactive oxygen species (ROS) in prostate cancer : OP022
Study of bladder cancer susceptibility conferred by 309 SNPs in 109 genes participating in inflammatory pathways : OP023
Expression of angiogenic factors in an orthotopic rat prostate tumour and in the surrounding non-malignant prostate tissue : OP024
Smarcc1 expression is upregulated in prostate cancer and positively correlated with tumor recurrence and dedifferentiation : OP25
SOCS-3 expression is regulated by fibro-blast growth factor (FGF)-2 in prostate cancer cell lines : OP26
Molecular characterization and expansion in vitro of clonogenic human prostate cancer cells : OP27
An analysis of the role of Cyr61, a member of the CCN family, in prostate cancer : OP28
Alpha-T-catenin (CTNNA 3) displays tumour specific monoallelic expression in urothelial carcinoma of the bladder (UCB) : OP29
Cytoplasmic E-cadherin (cdh1) staining is an independent predictor of time to recurrence in bladder cancer : OP30
P-Mark : a European quest for new biomarkers for prostate cancer
GATA-6 mediates human bladder smooth muscle differentiation : involvement of a novel enhancer element in regulating α-smooth muscle actin gene expression
DNA vaccination for prostate cancer : PP02
ERβ selective agonists a therapeutic opportunity for benign prostatic hyperplasia : PP03
Prostate carcinogenesis in a PSMA transgenic prostate tissue recombinant model : PP04
Serenoa repens extract induces cytosolic lipid accumulation in a panel of cancer cell lines, but is able to activate the intrinsic apoptotic pathways selectively in prostate cancer cells : PP05
Regulation of PBX 3 in prostate cancer : PP06
Global gene expression analysis for identification of genes involved in stromal androgen receptor signalling and regulation of human prostatic stem cells : PP07
Regulation of hAG-2 and hAG-3 transcripts in prostate cancer : PP08
2D-DIGE as a strategy to identify differentially expressed serum proteins between different grades of prostate cancer : PP09
Proteomic profiling of effect of prostate specific antigen (PSA) in prostate cancer cells : PP10
Brain derived metastatic prostate cancer DU-145 cells are effectively inhibited in vitro by guava (Psidium gujava L.) leaf extracts : PP11
β2-microglobu l in-mediated signaling drives prostate cancer bone metastasis : PP12
Substituted titanocenes : chemotherapy against metastatic renal-cell cancer?
Transcriptional regulation of E-cadherin (CDH1) in urothelial carcinoma of the bladder - the key players : PP14
Titanocene analogues induce apoptosis in the PWR-1E prostate epithelial cell line in a time and dose dependent manner : PP15
ADAM 15 disintegrin plays a critical role in prostate cancer metastasis by modulating metastatic- associated proteins and regulating endothelial interactions : PP16
Combined targeting of Androgen Receptor and Protein Kinase A signaling pathways in prostate cancer cells : PP17
Effects of docetaxel and novel titanocene analogues on cell death in prostate cancer following downregulation of Id-1 : PP18
Determination of novel urinary biomar-kers of prostate cancer using a 2D-DIGE proteome platform : PP19
PSA testing and prostate cancer diagnosis in the Republic of Ireland : PP20
Improved targeting of contrast agent microbubbles to αvβ3 integrin sites in the prostate : PP21
A novel high throughput screen identifies senescence-inducing activity of diaziqu- one in prostate cancer cells : PP22
Prodrug activation therapy kills prostate cancer cells in a three-dimensional culture model : PP23
A lentivirus vector system to track prostate cancer stem cell differentiation : PP24
Alterations of TGFβ signaling in a sub-population of stromal cells can promote prostate tumorigenesis : PP25
Cholesterol sensitivity of endogenous and myristoylated akt : PP26
Proteomic analyses of human prostate cancer progression cell lines : PP27
Protective effect of alfuzosin on neurogenic inflammatory responses and nociception in the rat lower urinary tract : PP28
Differential expression of the TSC22 domain family of transcription factors in normal prostate and prostate cancer : PP29
The International Bladder Cancer Bank -models for sharing tissue resources : PP30
TGF-beta1 downregulates Cx43 and restrains functional syncytia formation in cultured human bladder smooth muscle cells : PP31
Detection of TMPRSS2-ERG fusion transcripts and PCA3 in urinary sediments may improve diagnosis of prostate cancer : PP32
Up-regulation of TRAG-3 gene, a new predictor for chemotherapeutic resistance, associated with high- stage of bladder cancer : PP33
Comparison of the time-resolved fluorescence-based PCA3 test with the Gen-Probe PCA3 test for the detection of prostate cancer cells in urinary sediments : PP34
Proteins entrapped in PCa-derived exosomes as a source of novel serum markers : PP35
The effects of prostate cancer cell- derived soluble factors on the migration of prostate stromal cells : PP36
Mass spectroscopy imaging of prostate cancer tissue-a non target approach for protein biomarker discovery : PP37
Red fluorescent tdTomato reporter gene in the Fisher F344/AY-27 bladder cancer model : PP38
Preclinical evaluation of the prostate-specific oncolytic adenovirus Ad [I/PPT-E1A], : PP39
Carbonanotubes filled with carboplatin - a nanocarrier mediates inhibition of bladder cancer proliferation : PP40
Application of solifenacin in children with neurogenic bladder below 6 years of age : PP41
Endoscopic augmentation of neurogenic bladder in children with botulinum-A toxin : PP42
In vitro molecular evidence for better therapeutic efficacy of 2-methoxyestra-diol and endothelin a receptor antagonists combination in prostate cancer : PP43
DD3/PCA3 and AMACR in archived prostate biopsies : PP44
Silencing of the Nox4 NADP(H) oxidase enhances chemosensitivity of renal cell carcinoma to cisplatin : PP45
Hypoxia-inducible suicide gene therapy approach radiosensitises prostate cancer cells : PP46
IGFBP-3 inhibits prostate tumour cell adhesion, migration and invasion : PP47
An untested and new approach towards the development of glycosylation-related cancer signatures : PP48
Cystoscopy for in vivo tumor assessment in the orthotopic rat bladder urothelial cell carcinoma model : PP49
Role of microenvironmental VEGF distribution in human prostate angiogenesis : PP50
A bioinformatics approach to identify candidate apoptotic genes which may be the subject of epigenetic control in prostate cancer : PP51
Upregulation of muscarinic M2 receptors in detrusor muscle of patients with interstitial cystitis : PP52
Effects of coactivator CBP and androgen receptor on estrogen receptor beta in prostate cancer cell lines : PP53
Validation of self-reported race using the sequenom massarray compact system to quantitatively determine genomic ancestry : PP54
Stem cell characteristics of human prostate cancer cell lines : PP55
Cholesterol transport protein in therapeutic targeting of advanced prostate cancer : PP56
Identification of serum amyloid alpha by proteome analysis as a specific biomarker in serum of patients with renal cell carcinomas : PP57
In vitro evaluation of combined effects of conventional and new cytotoxic agents against a hormone-refractory prostate cancer (HRPC) cell line : PP58
Detection of human telomerase reverse transcriptase (hTERT) in superficial high-grade bladder cancer before and after BCG instillations : PP59
Urine fish (U-FISH) analysis as a diagnostic tool for recurrent bladder cancer : data on 50 cases
Copy number aberrations in prostate cancer cell lines by single nucleotide polymorphism array analysis : PP61
A role for the heparin-binding cytokines pleiotrophin and midkine in prostate cancer? : PP62
DHT rescues prostate cancer cells from Doxazocin induced apoptosis : PP63
Genome-wide copy number profiling and TNM staging of renal cell tumors : PP64
Radiolabelled Bothbesin analogues : a promising tool for imaging and radio-nucleide therapy for prostate cancer
Does dexamethasone work in androgen-independent prostate cancer (AIPC) by modulation of interleukin-8? : PP66
Role of noggin in osteolytic bone metastasis : PP67
A self-directed learning package in bladder cancer pathology using virtual microscopy : PP68
Knockdown of Mitomycin C resistance by Ras siRNA in vitro : PP69
Downregulation of FYN tyrosine kinase in prostate cancer by chromosomal deletion and promoter hypermethylation : PP70
Oct4 expression in benign and prostate cancer neuroendocrine cells : PP71
Chemotherapy combinations after docet- axel refractoriness in HRPC patients : NED used as a discriminator
Enhanced expression of hypoxia markers in cell lines and in clinical specimens of malignant prostate tissue : a factor in disease progression?
Effects of epigallocatechin-3-gallate (EGCG) on cell growth and apoptosis of prostate cancer lines and its interactions with dihydrotestosterone (DHT) : PP74
Transforming growth factor-beta (TGFβ) elicits differentiation of prostatic stroma in a lobe-specific manner : PP75
Combined treatment with lycopene and vitamin E; what is the optimal dose for inhibition of prostate cancer development in nude mice? : PP76
Lycopene inhibits the growth of various androgen (in) dependent cell lines in vitro : PP77
Identification of putative stem cells in human prostate cancer xenografts : PP78
New cryopreservation method for human prostate cancer xenografts : PP79
Towards the identification of PCA3 RNA- binding proteins : PP80
Progression into androgen independent prostate cancer alters endothelial cell gene expression in vitro : PP81
Nuclear androgen receptors recur in the epithelial and stromal compartments of malignant and non-malignant human prostate tissue after castration therapy : PP82
Decreased stroma androgen receptor staining in tumor and in surrounding non-malignant tissue is related to gleason score, tumor size, metastasis and outcome in prostate cancer : PP83
Prostate cancer stem cells : isolation and characterization
Non-invasive detection of bladder cancer by measurement of tumor-related transcript markers in urine : PP85
Soluble growth factors or bone micro-environment promote epithelial to mesenchymal transition and bone metastases in human prostate cancer : PP86